Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
Researchers compared Ropanicant and placebo to find out how the approaches affected depression symptoms in people with depression.
Understand this study
What did researchers investigate?
Researchers compared Ropanicant and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 214
- Sponsor
- Suven Life Sciences Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06836063
- Official title
Show the full official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate Efficacy and Safety of Ropanicant in Patients With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Rogers · Anaheim
31 more locations
- Culver City
- Glendale
- Lemon Grove
- Oceanside
- Orange
- Torrance
- Jacksonville
- Miami
- Orlando
- Pensacola
- Tampa
- Atlanta
- Decatur
- Savannah
- Chicago
- Bloomfield Hills
- Flowood
- Saint Charles
- Las Vegas
- Cherry Hill
- Marlton
- Brooklyn
- Cedarhurst
- Staten Island
- Raleigh
- Oklahoma City
- Memphis
- Austin
- Fort Worth
- Houston
- Everett
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Ropanicant and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Suven Life Sciences Limited.
Did this study involve medication?
Yes. The study involved medication, including Ropanicant and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
